Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07715669

Antidepressant Therapy for Improved Blood Vessel Health After Preeclampsia

Preeclampsia is a condition in pregnancy where a woman develops high blood pressure and other complications. Women who develop preeclampsia are 4 times more likely to have heart disease later in life. They are also more likely to have depression after pregnancy. Why they are more likely to develop these conditions is not known. It may be because their blood vessels were damaged during pregnancy. Changes in blood vessel health can predict heart disease. These changes have been recorded after pregnancy in women who had preeclampsia. These changes have also been recorded in women who have depression. In the previous phase of this award, we found that women who had preeclampsia in pregnancy had changes in blood vessel health after pregnancy. We also found that if these women were taking a medicine to treat depression, their blood vessel health was normal. This could mean that treatment for depression can also increase blood vessel health in women who had preeclampsia. In this project we will study how changes in blood vessel health are related to preeclampsia and depression in women who have had both. We will also study how medicine to treat depression can improve blood vessel health after preeclampsia. We will do this by measuring how blood vessels work in women who have had preeclampsia compared to women who did not, and in women who have depression and women who do not. This will tell us more about why risk for depression and heart disease is higher in women who have had preeclampsia. It will also help us understand if medicine for depression can reduce cardiovascular disease risk after preeclampsia.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18-24 years old, 12 weeks - 5 years post pregnancy one of the following:

  • a history of a normal pregnancy with a current diagnosis of depression,
  • a history of a normal pregnancy without a current diagnosis of depression,
  • a history of a preeclamptic pregnancy with a current diagnosis of depression, 4) and history of preeclamptic pregnancy without a current diagnosis of depression.

Exclusion criteria

history of cardiovascular, metabolic, and/or skin diseases current or history of tobacco/nicotine/ e-cigarette use history of gestational diabetes current antihypertensive or cholesterol-lowering medication currently pregnant allergy to materials used during the experiment (e.g. latex), known allergy to study drugs currently using SSRI medications

Treatment and study plan

Paroxetine Hydrochloride

Drug

Localized delivery of paroxetine HCl to the cutaneous microvasculature via intradermal microdialysis.

Ascorbic acid (vitamin C)

Drug

Localized delivery of ascorbic acid to the cutaneous microvasculature via intradermal microdialysis.

Primary outcomes

  1. Microvascular endothelium-dependent dilation response measured by laser-Doppler flowmetry

    Time frame: at the study visit, an average of 4 hours

    Cutaneous vascular conductance responses to local heating over a microdialysis fiber receiving treatments compared to lactated Ringer's solution (control).

  2. Nitric oxide-dependent dilation response measured by laser-Doppler flowmetry

    Time frame: at the study visit, an average of 4 hours

    Difference in cutaneous vascular conductance between local heating plateau and post-L-NAME plateau within each treated microdialysis site compared to lactated Ringer's (control).

Study contacts

Contact information is provided by the study sponsor or research team.

Anna Reid-Stanhewicz, PHD

CONTACT

[email protected]

319-467-1732

Sponsors and collaborators

Lead sponsor

Anna Stanhewicz, PhD

Other

Registry information

Official study title

Role of Antidepressant Therapy to Improve Vascular Function After Preeclampsia

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 20, 2026
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.